Gland Pharma Limited

NSE:GLAND.NS

1810.05 (INR) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

2024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q1
Revenue 14,017.115,374.515,451.5513,734.2412,086.937,850.119,382.8810,444.048,568.9810,864.5110,633.2510,804.6911,5398,485.098,594.198,3158,631.845,737.786,459.356,609
Cost of Revenue 10,582.6411,014.795,992.395,215.644,529.033,648.414,270.695,194.633,740.545,452.925,034.245,240.085,364.933,915.514,068.683,735.033,199.522,555.492,774.332,721.56
Gross Profit 3,434.464,359.719,459.168,518.67,557.94,201.75,112.195,249.414,828.445,411.595,599.015,564.616,174.074,569.584,525.514,579.975,432.323,182.293,685.023,887.44
Gross Profit Ratio 0.2450.2840.6120.620.6250.5350.5450.5030.5630.4980.5270.5150.5350.5390.5270.5510.6290.5550.570.588
Reseach & Development Expenses 489436530351457678512414410559699578438304434067.6217331252.34
General & Administrative Expenses 000000000000000029.350034.42
Selling & Marketing Expenses 000000000000000091.660033.67
SG&A 1,221.111,263.291,271.611,294.472,550.04516.19401533.28980.01957.06814.32823.18345.23405.7821.67785.58121.01695.79672.1268.09
Other Expenses 514.26421.47373.91531.55375.42389.39615.09656.24743.91-1,571.05456.69511.97618.38-792.85351.3203.5228.66-919.89252.881.93
Operating Expenses 1,710.111,699.296,948.686,090.815,271.512,892.942,592.582,647.622,478.332,233.562,388.232,059.792,064.041,539.322,132.841,849.61,546.931,008.281,809.621,479.28
Operating Income 1,724.352,660.422,884.392,959.342,286.391,133.543,134.73,258.032,350.113,174.613,210.783,504.924,110.033,030.262,392.672,933.893,885.392,174.011,875.42,408.16
Operating Income Ratio 0.1230.1730.1870.2150.1890.1440.3340.3120.2740.2920.3020.3240.3560.3570.2780.3530.450.3790.290.364
Total Other Income Expenses Net 458.1321.89-52.81-60.46326.27-22.03-26.2-17.21734.88630.23444.85501.73608.37459.17339.71-7.6314.61441.11196.1335.1
Income Before Tax 2,182.452,982.312,831.582,898.882,612.661,111.513,108.53,240.823,084.993,804.843,655.634,006.654,718.43,489.432,732.382,926.294,2002,615.122,071.52,743.26
Income Before Tax Ratio 0.1560.1940.1830.2110.2160.1420.3310.310.360.350.3440.3710.4090.4110.3180.3520.4870.4560.3210.415
Income Tax Expense 744.841,058.1913.02958.06671.64324.68789.01828.4793.3945.82925.34985.841,211.88885.34691.31737.721,064.1667.19530.51905.52
Net Income 1,437.611,924.21,918.561,940.821,941.02786.832,319.492,412.422,291.692,859.022,730.293,020.813,506.522,604.092,041.072,188.573,135.91,947.931,540.991,837.74
Net Income Ratio 0.1030.1250.1240.1410.1610.10.2470.2310.2670.2630.2570.280.3040.3070.2370.2630.3630.3390.2390.278
EPS 8.7311.6811.6511.7811.794.7814.0814.6513.9317.416.6218.3721.4116.3712.8313.419.2111.939.4411.25
EPS Diluted 8.7311.6811.6511.7811.784.7814.0814.6513.9217.2416.6218.3721.3716.3712.8213.419.2111.939.4411.25
EBITDA 2,643.973,586.53,937.813,772.343,314.961,508.963,510.813,624.753,443.134,117.523,945.814,277.994,981.183,743.862,993.623,180.524,447.132,851.332,370.592,792.23
EBITDA Ratio 0.1890.2330.2550.2750.2740.1920.3740.3470.4020.3790.3710.3960.4320.4410.3480.3830.5150.4970.3670.422